Genfit SA ( (GNFTF) ) has released its Q4 earnings. Here is a breakdown of the information Genfit SA presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Genfit SA is a late-stage biopharmaceutical company focused on developing treatments for rare and life-threatening liver diseases, with a strong emphasis on Acute-on-Chronic Liver Failure (ACLF) and a diverse portfolio of programs in various stages of development. In its latest earnings report for 2024, Genfit announced a net profit of €1.5 million, a significant turnaround from the previous year’s loss, driven by revenues of €67.0 million, including a substantial milestone payment from the commercial launch of Iqirvo® in the U.S. and Europe. The company also highlighted its strategic advancements in ACLF programs, including the successful execution of a Real-World data program and the expansion of its clinical trial reach, which have provided valuable insights for future development. Financially, Genfit strengthened its position with a non-dilutive royalty financing agreement worth up to €185 million, significantly extending its cash runway beyond 2027 and enabling further pipeline development. Looking ahead, Genfit remains focused on advancing its ACLF programs and exploring new therapeutic avenues, with several key data readouts and clinical milestones anticipated in 2025.